International Study on Treatment of Liver (HCC) Patients With IRE
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAngiodynamics, Inc.
About this trial
Procedural data will be recorded from patients with liver lesions from hepatocellular cancer who have been assessed by an appropriately constituted MDT (or equivalent) as appropriate to receive irreversible electroporation
Eligibility criteria
Qualifiers
Patients aged 18 years and over, able to provide informed consent and with clinical diagnosis of an HCC. Tissue confirmation of HCC prior to treatment is not standard of care and is therefore not required for this study.
Child-Pugh A up to A6.
Eastern Co-operative Oncology Group (ECOG) Score ≤ 2.
Rockwood Frailty Score ≤ 3.
Disqualifiers
Patients involved in other research studies.
Patients under the age of 18 years.
Inability to give informed consent.
Patients who are pregnant.
Trial design
Treatments tested in this trial
- Irreversible Electroporation
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov